Articles Referencing BMY

Pediatric Approval for MDCO/BMY's Recothrom - Analyst Blog

5/15/2013, 4:27 pm from Zacks.com in Investing, Business, Stocks

The Medicines Company ( MDCO ) recently gained US Food and Drug Administration (FDA) approval for the use of Recothrom in pediatric patients. The FDA expanded Recothrom's label following... Read >>

Amgen to Set Up JV in China - Analyst Blog

5/14/2013, 5:05 pm from Zacks.com in Investing, Business, Stocks

Amgen ( AMGN ) recently announced its intention to set up a joint venture (JV) in China with Zhejiang Beta Pharma Co., Ltd.  The JV will focus on the commercialization of Amgen's... Read >>

A Buyout Could Send This Leading Agriculture Stock Up 25%

5/14/2013, 12:30 pm from StreetAuthority in Investing, Investing Ideas, Stocks

Buyouts can be one of the quickest ways for investors to score a big profit. Buyout companies are almost always purchased at a premium that can give shareholders a nice pop. And with the... Read >>

Simcere Beats 1Q Earnings & Revenue Estimate - Analyst Blog

5/10/2013, 12:23 pm from Zacks.com in Investing, Business, Earnings, Stocks

Simcere Pharmaceutical Group ( SCR ) reported first quarter 2013 earnings of 9 cents per American Depositary Share (ADS) beating the Zacks Consensus Estimate by a penny. We note that each... Read >>

In Danish Laboratories, Hope Looms Large for a Permanent HIV Cure

5/8/2013, 1:42 pm from Minyanville in Investing, Stocks

So far HIV has eluded a permanent cure, yet many newly diagnosed patients can now control the virus with just one pill per day. Most lead relatively normal lives. In developing countries... Read >>

Good News for Bristol-Myers - Analyst Blog

5/6/2013, 4:23 pm from Zacks.com in Investing, Business, Stocks

Bristol-Myers Squibb Company ( BMY ) recently received positive news from the US Food and Drug Administration (FDA) when the US regulatory authority approved the pharma major's HIV... Read >>

Narrower-than-Expected Loss at Cadence - Analyst Blog

5/6/2013, 1:24 pm from Zacks.com in Investing, Business, Stocks

Cadence Pharmaceuticals, Inc. ( CADX ) posted an adjusted net loss of 13 cents per share in the first quarter of 2013, narrower than the Zacks Consensus Estimate of a loss of 14 cents. The... Read >>

This May Be The Best Pharmaceutical Stock for Income Investors

5/3/2013, 9:30 am from StreetAuthority in Investing, Investing Ideas, Stocks

As an income investor, I feel like I've hit the trifecta when I find a low-risk stock that also has consistent dividend growth and a fantastic yield. The high-quality dividend stocks I look... Read >>

Stocks Market News for May 1, 2013 - Market News

5/1/2013, 10:36 am from Zacks.com in Investing, US Markets

A strong rally in technology shares along with encouraging economic reports on the home front lifted major indices higher on Tuesday. Both the S&P 500 and the Nasdaq recorded their... Read >>

No News Becoming Bad News For Lexicon Pharmaceuticals

4/30/2013, 3:20 pm from SeekingAlpha in Investing, Stocks

By Stephen Simpson : Normally you would think that having a differentiated and proprietary diabetes compound with solid supporting data would make a biotech relatively popular. That would... Read >>

A Look Ahead: This Week's ETFs to Watch

4/28/2013, 5:28 pm from Benzinga in Investing, ETFs, International, Investing Ideas

Last week was another fine one for U.S. stocks as the broader market fought off an array of data points that can only be considered mixed at best to again close higher. With last week's 1.4... Read >>

Earnings Increase at The Medicines Co. - Analyst Blog

4/26/2013, 5:22 pm from Zacks.com in Investing, Business, Earnings, Stocks

The Medicines Company ( MDCO ) reported first quarter earnings of 24 cents per share, compared with the year-ago earnings of 14 cents per share. Including one-time items, the company... Read >>

Company News for April 26, 2013 - Corporate Summary

4/26/2013, 10:26 am from Zacks.com in Investing, Business, Investing Ideas, Stocks

•    Bristol Myers Squibb Co. (NYSE: BMY ) reported first quarter earnings per share of $0.41, in line with the Zacks Consensus Estimate •    Dominion... Read >>

Stocks Survive Once Again

4/25/2013, 5:15 pm from Minyanville in Investing, Stocks

Stocks rallied nicely early in the day, but turned downward in the afternoon on news that the German Bundesbank rejected the OMT bond purchasing program out of risk concerns. The morning joy... Read >>

Gilead Reports Encouraging HCV Data - Analyst Blog

4/24/2013, 7:10 pm from Zacks.com in Investing, Business, Stocks

Gilead Sciences, Inc. ( GILD ) recently announced detailed results from four phase III studies (NEUTRINO, FISSION, POSITRON and FUSION) which evaluated its candidate sofosbuvir (formerly... Read >>